A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)

15714EIDOSACT-EARLYOpenA Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)AG10-501NCT06563895IndustrialBothTreatmentDiseases Of The Circulatory SystemSheikh, FarooqMedstar Washington Hospital CenterMCRN - Heart Failure2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>